95 results
Page 4 of 5
8-K
EX-99.1
01jqg 34a
13 Oct 21
Liquidia Receives Favorable Ruling in Inter Partes Review
12:00am
424B3
tfdhmjxyj76vs6buxyqh
22 Sep 21
Prospectus supplement
4:06pm
8-K
EX-99.1
vi0769padmq0
19 Aug 21
FDA Completes On-site Pre-Approval Inspection of
4:05pm
8-K
EX-99.1
kjydit9j9amjc4g
12 Aug 21
U.S. Patent Trial and Trademark Appeal Board Decides to Institute
4:57pm
8-K
EX-99.1
fhheqadr6emu2kdi7klf
2 Jun 21
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
7:31am
8-K
EX-99.1
2x5vuw4
24 May 21
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
4:07pm
10-Q
lpcbzn2
13 May 21
Quarterly report
4:02pm
8-K
EX-99.1
810iu
13 May 21
Liquidia Reports First Quarter 2021 Financial Results
7:15am
8-K
EX-99.1
kdo3o9mfriiug3po7j9l
10 May 21
Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
6:36am
DEF 14A
s6h00zo
30 Apr 21
Definitive proxy
4:28pm
10-K
mni65o21z fghlq4
25 Mar 21
Annual report
5:01pm
8-K
EX-99.1
mob7om752g2tuonn8
23 Mar 21
Results of Operations and Financial Condition
7:41am
8-K
EX-99.1
ajr7stp
3 Mar 21
Entry into a Material Definitive Agreement
12:00am
8-K12B/A
EX-99.1
cd5 9002px754bsu8a
2 Feb 21
Notification of registration of securities (amended)
4:01pm
S-3
ndurr
16 Dec 20
Shelf registration
5:16pm
8-K
EX-99.1
o1tzwbidtk
16 Dec 20
Liquidia Corporation Announces Chief Executive Officer Transition
12:00am
8-K
EX-99.1
xtegw1sagb4lx2cr7ly
1 Dec 20
Departure of Directors or Certain Officers
8:41am